PURPOSE: High-quality, well-coordinated cancer survivorship care is needed yet barriers remain owing to fragmentation in the United States health care system. This article is a nationwide survey of barriers perceived by primary care physicians (PCPs) and medical oncologists (MOs) regarding breast and colorectal cancer survivorship care beyond 5 years after treatment. METHODS: The Survey of Physician Attitudes Regarding the Care of Cancer Survivors was mailed out in 2009 to a nationally-representative sample (n = 3,596) of US PCPs and MOs. Ten physician-perceived cancer survivorship care barriers/concerns were compared between the two provider types. Using weighted multinomial logistic regression, we modeled each barrier, adjusting for physician demographics, reimbursement, training, and practice characteristics. RESULTS: We received responses from 2,202 physicians (1,072 PCPs; 1,130 MOs; 65.1% cooperation rate). In adjusted patient-related barriers models, MOs were more likely than PCPs to report patient language barriers (odds ratio, [OR], 1.72; 95% CI, 1.22 to 2.42), insurance restrictions impeding test/treatment use (OR, 1.42; 95% CI, 1.03 to 1.96), and patients requesting more aggressive testing (OR, 4.08; 95% CI, 2.73 to 6.10). In adjusted physician-related barriers models, PCPs were more likely to report inadequate training (OR, 3.06; 95% CI, 2.03 to 4.61) and ordering additional tests/treatments because of malpractice concerns (OR, 1.87; 95% CI, 1.20 to 2.93). MOs were more likely to report uncertainty regarding general preventive care responsibility (often/always: OR, 1.97; 95% CI, 1.13 to 3.43; sometimes: OR, 2.16; 95% CI, 1.60 to 2.93). CONCLUSION: MOs and PCPs perceive different cancer follow-up care barriers/concerns to be problematic. Resolving inadequate training, malpractice-driven test ordering, and preventive-care responsibility concerns may require continuing education, explicit guidelines, and survivorship care plans. Reviewing care plans with survivors may also reduce patients' requests for unnecessary testing.
PURPOSE: High-quality, well-coordinated cancer survivorship care is needed yet barriers remain owing to fragmentation in the United States health care system. This article is a nationwide survey of barriers perceived by primary care physicians (PCPs) and medical oncologists (MOs) regarding breast and colorectal cancer survivorship care beyond 5 years after treatment. METHODS: The Survey of Physician Attitudes Regarding the Care of Cancer Survivors was mailed out in 2009 to a nationally-representative sample (n = 3,596) of US PCPs and MOs. Ten physician-perceived cancer survivorship care barriers/concerns were compared between the two provider types. Using weighted multinomial logistic regression, we modeled each barrier, adjusting for physician demographics, reimbursement, training, and practice characteristics. RESULTS: We received responses from 2,202 physicians (1,072 PCPs; 1,130 MOs; 65.1% cooperation rate). In adjusted patient-related barriers models, MOs were more likely than PCPs to report patient language barriers (odds ratio, [OR], 1.72; 95% CI, 1.22 to 2.42), insurance restrictions impeding test/treatment use (OR, 1.42; 95% CI, 1.03 to 1.96), and patients requesting more aggressive testing (OR, 4.08; 95% CI, 2.73 to 6.10). In adjusted physician-related barriers models, PCPs were more likely to report inadequate training (OR, 3.06; 95% CI, 2.03 to 4.61) and ordering additional tests/treatments because of malpractice concerns (OR, 1.87; 95% CI, 1.20 to 2.93). MOs were more likely to report uncertainty regarding general preventive care responsibility (often/always: OR, 1.97; 95% CI, 1.13 to 3.43; sometimes: OR, 2.16; 95% CI, 1.60 to 2.93). CONCLUSION: MOs and PCPs perceive different cancer follow-up care barriers/concerns to be problematic. Resolving inadequate training, malpractice-driven test ordering, and preventive-care responsibility concerns may require continuing education, explicit guidelines, and survivorship care plans. Reviewing care plans with survivors may also reduce patients' requests for unnecessary testing.
Authors: Laura-Mae Baldwin; Walter Adamache; Carrie N Klabunde; Kevin Kenward; Celia Dahlman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Carla Parry; Erin E Kent; Angela B Mariotto; Catherine M Alfano; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10 Impact factor: 4.254
Authors: Tenbroeck Smith; Kevin D Stein; C Christina Mehta; Chiewkwei Kaw; James L Kepner; Trent Buskirk; Jeremy Stafford; Frank Baker Journal: Cancer Date: 2007-01-01 Impact factor: 6.860
Authors: James L Khatcheressian; Antonio C Wolff; Thomas J Smith; Eva Grunfeld; Hyman B Muss; Victor G Vogel; Francine Halberg; Mark R Somerfield; Nancy E Davidson Journal: J Clin Oncol Date: 2006-10-10 Impact factor: 44.544
Authors: Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: Arnold L Potosky; Paul K J Han; Julia Rowland; Carrie N Klabunde; Tenbroeck Smith; Noreen Aziz; Craig Earle; John Z Ayanian; Patricia A Ganz; Michael Stefanek Journal: J Gen Intern Med Date: 2011-07-22 Impact factor: 5.128
Authors: Carrie N Klabunde; Paul K J Han; Craig C Earle; Tenbroeck Smith; John Z Ayanian; Richard Lee; Anita Ambs; Julia H Rowland; Arnold L Potosky Journal: Fam Med Date: 2013 Jul-Aug Impact factor: 1.756
Authors: Carol A Rosenberg; Carol Flanagan; Bruce Brockstein; Jennifer C Obel; Leon H Dragon; Douglas E Merkel; Elaine L Wade; Teresa M Law; Janardan D Khandekar; Thomas A Hensing Journal: J Cancer Surviv Date: 2015-07-16 Impact factor: 4.442
Authors: Callie Berkowitz; Deborah H Allen; Jennifer Tenhover; Leah L Zullig; John Ragsdale; Jonathan E Fischer; Kathryn I Pollak; Bridget F Koontz Journal: J Cancer Educ Date: 2018-12 Impact factor: 2.037
Authors: Heather B Neuman; Nicole M Steffens; Nora Jacobson; Amye Tevaarwerk; Bethany Anderson; Lee G Wilke; Caprice C Greenberg Journal: Ann Surg Oncol Date: 2015-10-16 Impact factor: 5.344
Authors: Jessica L Krok-Schoen; Jennifer DeSalvo; Dori Klemanski; Christian Stephens; Anne M Noonan; Seuli Brill; Maryam B Lustberg Journal: Support Care Cancer Date: 2019-05-22 Impact factor: 3.603
Authors: Nicole P M Ezendam; Kim A H Nicolaije; Roy F P M Kruitwagen; Johanna M A Pijnenborg; M Caroline Vos; Dorry Boll; Marjo van Bommel; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2014-05-28 Impact factor: 4.442
Authors: Simon J Craddock Lee; Mark A Clark; John V Cox; Burton M Needles; Carole Seigel; Bijal A Balasubramanian Journal: J Oncol Pract Date: 2016-10-31 Impact factor: 3.840